[at Seeking Alpha] – The recent market sell off has provided a lot of great entry points into dividend paying stocks, like the ones covered here and here. This article is about another dividend growth giant, Johnson & Johnson …
Read more on this.
Johnson & Johnson (JNJ), valued at $248.34B, started the session at $87.63.
A quick look at the market, the company’s traded between $87.55 to $88.50 and has traded between $74.68 and $95.99 over the past 12 months.
JNJ shares are currently priced at 14.95x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 9.65x forward p/e ratio.
The company pays shareholders $2.64 per share in dividend income per year, for a current yield of 3.00%.
Consensus earnings for the current quarter by the 16 sell-side analysts covering the stock is an estimate of $1.48 per share, which would be $0.04 better than the year-ago quarter and a $0.00 sequential decrease. The full-year EPS estimate is $5.84 which would be a $0.32 better than last year’s full-year earnings.
The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $18.04 Billion. If realized, that would be a 3.09% increase over the year-ago quarter.
More recently, Barclays downgraded JNJ from Overweight to Equal Weight (Jan 10, 2014). Previously, RBC Capital Mkts upgraded JNJ from Sector Perform to Outperform.
Given all the information above, we should disclose to readers that the average price target is $101.02, which is 15.28% above than it opened this morning.
Johnson & Johnson (NYSE:JNJ), together with its subsidiaries, engages in the research and development, manufacture and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics.
Tag Helper ~ Stock Code: JNJ | Common Company name: Johnson & Johnson | Full Company name: Johnson & Johnson (NYSE:JNJ) .